Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
Indivior Pharmaceuticals, Inc. is the principal U.S. operating subsidiary of Indivior PLC, a specialty pharmaceutical company focused on the development and commercialization of medicines to treat substance use disorders and serious mental illnesses. The company operates within the biopharmaceutical and addiction treatment industries, with a primary emphasis on opioid use disorder (OUD). Its business is centered on prescription medications that combine pharmacological innovation with delivery technologies designed to improve adherence and clinical outcomes.
Indivior traces its origins to a 2014 demerger from Reckitt Benckiser Group, where its addiction treatment business had been incubated. Since becoming an independent publicly traded company, Indivior has narrowed its strategic focus on OUD and related disorders, transitioning from legacy products toward long-acting injectable therapies. The company’s positioning is built around established brand recognition in OUD treatment and a portfolio that spans both daily and extended-release formulations.
Business Operations
Indivior generates revenue primarily through the sale of branded prescription medications, with its operations organized around a single core reporting segment focused on Addiction Treatment Medicines. Key marketed products include Suboxone Film, Sublocade, and Perseris, which are prescribed by healthcare providers and reimbursed through a mix of commercial insurance, government healthcare programs, and institutional purchasers. Product sales in the United States account for the substantial majority of total revenue.
Operationally, Indivior relies on a combination of internal research and development capabilities and outsourced manufacturing and distribution partners. The company maintains commercial, medical affairs, and regulatory functions in-house, while manufacturing is largely conducted through third-party contract manufacturers. Indivior Pharmaceuticals, Inc. serves as the main U.S. commercial entity, while intellectual property ownership and certain strategic functions reside at the Indivior PLC level.
Strategic Position & Investments
Indivior’s strategy emphasizes growth through long-acting injectable therapies, lifecycle management of existing products, and selective investment in adjacent psychiatric indications. A central pillar of this strategy is continued expansion of Sublocade, which is positioned as a differentiated, once-monthly injectable treatment for OUD. The company has also invested in next-generation depot and implant technologies intended to reduce diversion risk and improve treatment compliance.
In addition to organic development, Indivior has pursued targeted acquisitions and licensing arrangements to strengthen its pipeline, though large-scale transformational acquisitions have been limited. The company has allocated capital toward clinical development programs and post-marketing studies designed to expand label indications and reinforce payer coverage. Where public disclosures differ on the long-term scale of pipeline diversification beyond addiction treatment, data inconclusive based on available public sources.
Geographic Footprint
Indivior operates primarily in North America, with the United States representing its largest and most commercially significant market. The company’s global headquarters are located in the United Kingdom, while U.S. commercial operations are managed through Indivior Pharmaceuticals, Inc., which serves as the hub for sales, marketing, and market access activities.
Beyond the U.S., Indivior maintains a presence in parts of Europe, Australia, and selected international markets through subsidiaries and distribution partners. International revenue contributions are materially smaller than U.S. sales, but these regions support the company’s long-term objective of diversified geographic exposure and regulatory engagement across multiple healthcare systems.
Leadership & Governance
Indivior is led by an executive team with experience in specialty pharmaceuticals, regulatory affairs, and commercial execution in controlled substance markets. Leadership emphasizes a strategy centered on ethical commercialization, patient access, and regulatory compliance, reflecting the sensitive nature of addiction treatment products.
Key executives include:
- Mark Crossley – Chief Executive Officer
- Joe Ciaffoni – Chair of the Board
- Data inconclusive based on available public sources regarding the current tenure and titles of certain other named executive officers, as disclosures vary across reporting periods.
The company is governed by a board of directors responsible for oversight of strategy, risk management, and compliance, with committees aligned to audit, compensation, and corporate governance responsibilities.